This is a transformative regulatory catalyst that removes the last postmarketing requirement and expands the addressable market. Monitor upcoming quarterly results for initial pediatric prescription trends and any guidance update on revenue contribution.
MNKD drugs
MNKD drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 2 $3.43entry
- T+1 · 6mo ago −2.04%α −1.35% · $3.36
- T+5 · 5mo ago +4.08%α +7.05% · $3.57
- T+20 · 5mo ago +18.08%α +19.64% · $4.05
- T+60 · 3mo ago +19.24%α +18.13% · $4.09
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MannKind announced FDA approval of Afrezza (insulin human) Inhalation Powder for pediatric use in children and adolescents aged 6+ with type 1 and type 2 diabetes. This also fulfills the last remaining postmarketing requirement from the original 2014 approval, removing a key regulatory overhang and opening a new patient population of over 350,000 U.S. children with diabetes.
Key Facts
- FDA approved Afrezza for pediatric use in patients aged 6 and older with type 1 and type 2 diabetes.
- Over 350,000 U.S. children and adolescents live with diabetes, majority type 1 requiring lifelong insulin.
- Pediatric sBLA fulfills the last remaining postmarketing requirement from the original June 27, 2014 approval letter.
- Approval date: May 29, 2026; 8-K filed June 2, 2026.
Financial Impact
Opens a new pediatric market of >350,000 patients; no specific revenue guidance provided in filing.
Risk Factors
- Pediatric adoption may be slower than expected due to competition from established insulin delivery methods.
- No financial terms or revenue projections disclosed in the filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-252544 |
| Document: 0001193125-26-252544-index-headers.html | 0001193125-26-252544 |
| Document: 0001193125-26-252544-index.html | 0001193125-26-252544 |
| Document: 0001193125-26-252544.txt | 0001193125-26-252544 |
Track record
17 reports on MNKD
6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +20.00% at T+60 after the May 27, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.23 Now $3.96 −6.38% settles Dec 9
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Bearish 5/10 Entry $3.90 Now $3.96 −1.54% settles Dec 7
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $3.73 Now $3.96 +6.17% settles Dec 2
- Jul 29, 202615w ago Press Release Bullish 6/10 Entry $3.85 to $4.09 Now $3.96 +2.86% ▲ +6.23% +1.21% vs SPY
- Jul 24, 202616w ago 8-K Mixed 6/10 Entry $3.95 to $4.07 Now $3.96 +0.25% ▲ +3.04% −0.26% vs SPY
- Jul 17, 202617w ago Insider Cluster Neutral 3/10 Entry $3.98 to $3.90 Now $3.96 −0.50% ▼ −2.01% −6.13% vs SPY
- Jun 3, 202623w ago Press Release Neutral 5/10 Entry $3.36 to $4.52 Now $3.96 +17.86% ▲ +34.52% +35.52% vs SPY
- Jun 2, 202623w ago 8-K Bullish 7/10 Viewing Entry $3.43 to $4.05 Now $3.96 +15.45% ▲ +18.08% +19.64% vs SPY
- May 29, 202624w ago Press Release Bullish 8/10 Entry $3.77 to $4.24 Now $3.96 +5.04% ▲ +12.47% +14.26% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers